RxDoctor Payments DataLook up a doctor →

David Morris, MD

Urology · Hendersonville, TNNPI 1194841452

Payments from drug & device makers

$7,336,820in general payments, 2019–2025

Across 2,677 payments — averaging $2740.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1.8M
  • Janssen Research & Development, LLC$1.5M
  • Merck$1.3M
  • Clovis Oncology, Inc.$741K
  • AstraZeneca$593K
  • Bayer$423K
  • plus $1.1M from 54 others
$466in research payments, 2019–2025

Across 2 payments — averaging $233.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$466

What the payments were for

  • Consulting fees$185,55821%
  • Speaking & faculty fees$570,06465%
  • Travel & lodging$71,4478%
  • Food & beverage$43,7425%
  • Education$3380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer166$1,788,193
Janssen Research & Development, LLC229$1,450,588
Merck204$1,253,611
Clovis Oncology, Inc.76$740,836
AstraZeneca132$593,310
Bayer366$422,527
Dendreon Pharmaceuticals LLC143$164,438
Urogen Pharma, Inc.53$142,934
Johnson & Johnson(2 entities)276$138,955
Astellas Pharma US Inc229$132,394
Sumitomo Pharma America, Inc.98$82,980
Veru Inc.7$77,407
Epizyme, Inc.17$56,603
Pharmaand GmbH7$55,289
SN Holdings, LLC63$39,353
Myovant Sciences Inc.59$30,473
Astellas Pharma Global Development9$27,417
Eli Lilly4$25,251
Urogpo LLC32$17,714
Exelixis Inc.46$14,606
Astrazeneca UK Limited6$12,490
Blue Earth Diagnostics32$12,077
Janssen Scientific Affairs, LLC7$10,321
Progenics Pharmaceuticals, Inc.19$8,292
Tolmar, Inc.23$7,316
Amgen23$5,616
Tolmar Pharmaceuticals, Inc.22$3,937
Myriad Genetic Laboratories, Inc.30$3,621
Spectrum Pharmaceuticals Inc.2$2,850
Ferring Pharmaceuticals Inc.17$2,420
Verity Pharmaceuticals Inc.14$2,279
Novartis10$2,125
AbbVie(2 entities)59$1,834
Daiichi Sankyo Inc.2$1,645
Janssen Global Services, LLC1$500
Endo Pharmaceuticals Inc.22$473
Coloplast16$315
Axonics, Inc.14$248
Urovant Sciences Inc13$243
Boston Scientific12$239
Rochester Medical Corporation13$232
Telix Pharmaceuticals7$227
Laborie Medical Technologies Corp.5$225
Medtronic4$210
Immunitybio, Inc.4$203
Cardinal Health Inc1$202
Angiodynamics, Inc.4$166
Sun Pharmaceutical Industries Inc.6$148
C. R. Bard, Inc. & Subsidiaries5$131
Stryker4$114
Valencia Technologies Corporation3$103
Clarus Therapeutics Inc.8$97
Accord Healthcare, Inc.5$96
Antares Pharma, Inc.6$96
Abbott2$92
Eisai Inc.4$87
180 Medical, Inc.4$83
Procept Biorobotics Corporation3$76
Vertex2$63
Olympus America Inc.3$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,336,820 in reported general payments places this provider in the 95th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,237,320
Medicare patients
1,061
Services billed
11,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide311$4,386,172
XtandiEnzalutamide322$4,284,938
NubeqaDarolutamide110$1,408,342
OrgovyxRelugolix492$1,258,155
Abiraterone Acetate321$715,173
MyrbetriqMirabegron320$205,274
GemtesaVibegron136$76,341
Solifenacin Succinate370$29,154
Tamsulosin Hcl1,141$16,530
Finasteride686$11,126
XyostedTestosterone Enanthate12$7,159
Testosterone34$5,978
Estradiol87$5,652
PremarinEstrogens, Conjugated11$4,567
Testosterone Cypionate157$4,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$132,394$4,490,212642 claims
Johnson & JohnsonErleada$138,955$4,386,172311 claims
BayerNubeqa$422,527$1,408,342110 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$82,980$1,334,496628 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$10,321$715,173321 claims
Antares Pharma, Inc.Xyosted$96$7,15912 claims
PfizerPremarin$1,788,193$4,56711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 urology providers in Tennessee.

Other urology in Hendersonville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →